Conventional wisdom that provider capacity drives cost questioned in new study

Remember the idea that coordination will improve care? Well, if physicians do not get timely reports from other providers, their patients seem to have lower costs!!!  This from a new study out from the Center for Studying Health System Change. 

More importantly, this paper throws cold water on the idea that providers generate a lot of unnecessary cost to fill up excess capacity in the delivery system.   As you know, conventional wisdom driven by the Dartmouth Atlas and other studies has it that that care utilization and cost can vary sharply across regions without being tied to better outcomes, e.g. when there are a lot of ICU beds in a region, then a lot of patients end up in ICUs; when there are a lot of specialists, a lot of specialists tend to get seen, etc. Some studies suggest as much as a 50% cost gap between top decile and bottom decile geographies.

But this new study found – once you adjust for health status of the patient — no real correlation between cost and a variety of provider system structural features (such as bed capacity).

Implication:

Even if you can change the delivery system structure, don’t expect any real reduction in cost.  Therefore, the study suggests, a lot of public policy and health plan strategy may be focused on a much smaller cost reduction prize than many people hope.

Share

Keep up with the Recon Strategy Insights

Get an email each time Recon takes an analytical look behind select developments in healthcare.

Suggested Articles

For years, digital biomarkers have seemed like a promising way to transform drug clinical trials, yet their adoption journey has been uneven.  We’ve watched as the excitement for Proteus's ingestible …
In February 2025, the FDA gave IND approval to United Therapeutics for the first xenotransplantation clinical trial, which followed a series of high-profile transplants via the compassionate use pathw…
Introduction In 2017, the FDA approved Luxturna for the treatment of Leber’s congenital amaurosis (LCA), marking the first gene therapy used for an inherited disease in the U.S. The curative potential…
We use cookies
This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.